The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes |
| |
| Authors: | Nobuya Inagaki MD PhD Eiichi Araki MD PhD Tomonori Oura MS Akiko Matsui PhD Masakazu Takeuchi PhD Yukio Tanizawa MD PhD |
| |
| Affiliation: | 1. Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan;2. Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan;3. Eli Lilly Japan K.K., Kobe, Japan;4. Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan |
| |
| Abstract: | The efficacy and safety of once‐weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open‐label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined. There were no clinically relevant differences in glycated haemoglobin (HbA1c) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with BG alone compared to the other two groups (SU alone and SU + BG). Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG. The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group. Incidence of hypoglycaemia was highest in combination with SU for both treatments. For patients with T2D, dulaglutide added to concomitant BG may be more likely to result in weight loss than dulaglutide added to concomitant SU. |
| |
| Keywords: | dulaglutide
GLP‐1 receptor agonist insulin glargine subgroup analysis type 2 diabetes |
|
|
